Michael Borys (Bristol- Myers Squibb) Incorporation of QbD elements into the development and characterization of a second generation process by Borys, Michael & Abu-Absi, Nicholas
Engineering Conferences International
ECI Digital Archives
Cell Culture Engineering XV Proceedings
Spring 5-12-2016
Michael Borys (Bristol- Myers Squibb)
Incorporation of QbD elements into the
development and characterization of a second
generation process
Michael Borys
Bristol-Myers Squibb Company
Nicholas Abu-Absi
nicholas.abuabsi@bms.com, nicholas.abuabsi@bms.com
Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv
Part of the Biomedical Engineering and Bioengineering Commons
This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture
Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Michael Borys and Nicholas Abu-Absi, "Michael Borys (Bristol- Myers Squibb) Incorporation of QbD elements into the development
and characterization of a second generation process" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum,
Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/
cellculture_xv/54
INCORPORATION OF QbD ELEMENTS INTO THE DEVELOPMENT AND CHARACTERIZATION OF A 
SECOND GENERATION PROCESS 
 
Nicholas R. Abu-Absi, Bristol-Myers Squibb Company 
nicholas.abuabsi@bms.com@bms.com 
Amanda M. Lewis, Bristol-Myers Squibb Company 
Xuankuo Xu, Bristol-Myers Squibb Company 
Chittoor Narahari, Bristol-Myers Squibb Company 
Zizhuo Xing, Bristol-Myers Squibb Company 
Michael C. Borys, Bristol-Myers Squibb Company 
Zheng Jian Li, Bristol-Myers Squibb Company 
 
 
Key Words: QbD, scale down model, scale up, design of experiments, design space 
 
QbD principles are readily incorporated into mammalian cell processes to streamline process development and 
characterization. A key enabler of the implementation of these principles has been widespread adoption of 
platform technologies by the industry. This allows easy and efficient navigation of the QbD roadmap laid out in the 
A-Mab case study over the course of the development lifecycle of a product. 
Here we examine the case of a 2nd generation process for a legacy product that was originally developed and 
approved using the traditional approach to process development and characterization. The goal of the 2nd 
generation process was to achieve several fold increases to productivity while achieving similar process 
performance across scales. Furthermore, comparability profiles of quality attributes must be maintained to ensure 
treatment efficacy and patient safety, and to streamline the regulatory approval process. To meet these 
constraints, it was necessary to make significant deviations from the platform process. 
This presentation outlines some of the challenges encountered during process development, tech transfer, and 
process characterization and how QbD principles were incorporated at each of the stages. Specifically, advanced 
metabolomics and proteomics methods were used to understand and eliminate differences in process 
performance after tech transfer to manufacturing scale and small scale bioreactor operations were optimized to 
ensure an appropriate scale down model. Risk assessments were used to guide process characterization efforts 
and custom DOE approaches were used to minimize bioreactor experiments. The experimental data were then fit 
to models to understand the design space and used to establish quantitative criteria to guide parameter 
classification. The models were verified through additional experiments and raw material variability was accounted 
for to improve robustness. The examples provided here demonstrate the advantages of incorporating QbD 
principles into the development cycle of biologics processes even in situations of compressed timelines and off-
platform processes. 
 
